Mylan Launches Generic Version of Revatio® Tablets
Mylan N.V. (NASDAQ:MYL)
Historical Stock Chart
5 Years : From Jun 2011 to Jun 2016
PITTSBURGH, Nov. 13, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Sildenafil Citrate Tablets, 20 mg. This product is the generic version of Pfizer's Revatio®, which is indicated for the treatment of pulmonary arterial hypertension in adults to improve exercise ability and delay clinical worsening.
Revatio Tablets, 20 mg, had U.S. sales of approximately $338.7 million for the 12 months ending September 30, 2012, according to IMS Health. Mylan has begun shipping this product.
Currently, Mylan has 172 ANDAs pending FDA approval representing $79.5 billion in annual sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $21.2 billion in annual brand sales, for the 12 months ending June 30, 2012, according to IMS Health.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.